To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment
Purpose
This is a Phase 2 study of the efficacy, safety, tolerability and pharmacokinetics of two doses of EXPD-101 in participants with COPD. Study participants will be randomized to receive either study drug or placebo administered once daily for 52 weeks.
Condition
- Chronic Obstructive Pulmonary Disease (COPD)
Eligibility
- Eligible Ages
- Between 40 Years and 85 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Provided written informed consent for the study 2. Body mass index (BMI) ≥ 18.5 kg/m2 and < 35 kg/m2 at screening (weight ≥ 50 kg for males and ≥ 45 kg for females) 3. Diagnosis of COPD for at least 1 year 4. COPD with physician-confirmed diagnosis of chronic bronchitis (persistent, productive cough and sputum for at least 3 months in the past year) 5. At least 2 moderate or > 1 severe exacerbation within 12 months prior to screening 6. Current or ex-tobacco smokers with history of ≥ 10 pack-years (1 pack year = 20 cigarettes smoked per day for 1 year); 7. Stable maintenance therapy with either dual or triple inhaled therapy for ≥ 3 months prior to enrollment per below: 1. Dual therapy: long-acting beta-2 agonist/muscarinic antagonist (LABA/LAMA) or inhaled corticosteroids (ICS)/LAMA, or ICS/LABA OR 2. Triple therapy: ICS/LAMA/LABA 8. Post-BD FEV1/FVC < 0.7 and post-BD FEV1(% predicted) ≥ 40% at Screening 9. COPD Assessment Test (CAT) score ≥ 10 at Screening 10. If participant is of childbearing potential, must commit to practicing highly effective methods of birth control and not donating eggs during the study and at least 14 days after the last dose. 11. Male participants commit to the following during the study and for at least 14 days after the last dose: 1. Practice true sexual abstinence (refrain from heterosexual intercourse) 2. Use a condom with any female partner of childbearing potential and ensure that the partner uses a highly effective contraceptive method (eg, IUD/IUS, combined hormonal contraception, progestogen-only contraception, or bilateral tubal occlusion). 3. Be vasectomized (≥ 3 months prior to screening) 4. Refrain from donating sperm during the Treatment Period and for at least 14 days after the last dose of the IP
Exclusion Criteria
- COPD exacerbation within the 4 weeks prior to randomization. 2. Clinically important pulmonary disease other than COPD (eg, asthma, active lung infection, clinically significant bronchiectasis, pulmonary fibrosis, cystic fibrosis, lung cancer, alpha-1 antitrypsin deficiency, tuberculosis). 3. Significant immunodeficiency and/or positive serological tests for hepatitis B, hepatitis C, or known human immunodeficiency virus (HIV) infection. 4. Pneumonia requiring antibiotics or antiviral medication within 28 days prior to Visit 1. 5. History of clinically significant infection (excluding pneumonia), acute upper or lower respiratory infection, requiring antibiotics or antiviral medication within 14 days prior to Visit 1. 6. Evidence of active liver disease (with or without ongoing treatment) 7. Participants with a QT interval, from the ECG conducted at Screening Visit 1, corrected with Fridericia's formula (QTcF) > 450 msec (or QTcF > 480 msec in participants with bundle branch block). 8. Current or history, within the past year of Visit 1, of substance and/or alcohol abuse. 9. History of cancer except: 1. Participants who have had basal cell carcinoma, localized squamous cell carcinoma of the skin or in situ carcinoma of the cervix are eligible to participate in the study provided that curative therapy was completed at least 12 months prior to Visit 1 2. Participants who have had other malignancies are eligible provided that curative therapy was completed at least 5 years prior to Visit 1 10. Any clinically significant abnormal findings in physical examination, vital signs, hematology, clinical chemistry, or urinalysis during Screening Period, which in the opinion of the investigator, may put the participant at risk because of his/her participation in the study, or may influence the results of the study, or the participant's ability to complete the entire duration of the study. 11. Known history of allergy or reaction to any component of the investigational product formulation 12. Current treatment with biologic drugs for COPD (eg, dupilumab, mepolizumab) or use of Therapeutics, biologics within 5 half-lives or 4 months, whichever is longer, from randomization 13. Current long-term treatment with oxygen therapy > 12 hours per day 14. Use of immunoglobulin or blood products in 30 days prior to Screening 15. Received a live attenuated vaccine within 30 days prior to Screening 16. Participants who are participating in the acute phase of a pulmonary rehabilitation program, i.e. who started rehabilitation < 4 weeks prior to screening (Note: participants in the maintenance phase of a rehabilitation program can be included). 17. History or active conditions associated with the onset of non-hereditary palmoplantar keratosis: 18. Have any tooth that can potentially cause pain or infection as noted in the oral exam unless they are corrected before the study 19. Has active periodontal disease and are either: 1. Currently treated by a dentist for this condition or 2. Expected to have periodontal disease-related procedures within the study period 20. Are scheduled to have tooth extraction that will occur during the study period
Study Design
- Phase
- Phase 2
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Treatment
- Masking
- Double (Participant, Investigator)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Experimental EXPD-101/FXS7553 Dose 1 |
Participants will receive EXPD-101/FXS7553 Dose 1, orally, once daily, for 52 weeks. |
|
|
Experimental EXPD-101/FXS7553 Dose 2 |
Participants will receive EXPD-101/FXS7553 Dose 2, orally, once daily, for 52 weeks. |
|
|
Placebo Comparator Placebo |
Participants will receive a EXPD-101/FXS7553-matching placebo, tablets orally, once daily, for 52 weeks. |
|
Recruiting Locations
DM Clinical Research - Phoenix
Phoenix, Arizona 85012
Phoenix, Arizona 85012
California Medical Research Associates Inc.
Northridge, California 91324
Northridge, California 91324
Lynn Institute of Denver
Aurora, Colorado 80012
Aurora, Colorado 80012
Clinical Site Partners, LLC Leesburg dba Flourish Research
Leesburg, Florida 34748
Leesburg, Florida 34748
Suncoast Research Group, LLC Miami - Little Havana dba Flourish Research
Miami, Florida 33135
Miami, Florida 33135
Optimal Research Sites
Orange, Florida 32763
Orange, Florida 32763
DM Clinical Research-Indianapolis
Indianapolis, Indiana 46254
Indianapolis, Indiana 46254
Cotton O'Neil Clinical Research Center
Topeka, Kansas 66606
Topeka, Kansas 66606
DM Clinical Research - Philadelphia
Philadelphia, Pennsylvania 19107
Philadelphia, Pennsylvania 19107
DM Clinical Research- Tomball
Tomball, Texas 77375
Tomball, Texas 77375
Burke Internal Medicine, Inc.
Burke, Virginia 22015
Burke, Virginia 22015
More Details
- Status
- Recruiting
- Sponsor
- Expedition Therapeutics, Inc